<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00070161</url>
  </required_header>
  <id_info>
    <org_study_id>REBACCCWFU-97100</org_study_id>
    <secondary_id>U10CA081851</secondary_id>
    <nct_id>NCT00070161</nct_id>
  </id_info>
  <brief_title>Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor</brief_title>
  <official_title>Donepezil and EGb761 in Improving Neurocognitive Function in Patients Who Have Previously Undergone Radiation Therapy for Primary Brain Tumor or Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Donepezil and EGb761 may be effective in improving neurocognitive function (such&#xD;
      as thinking, attention, concentration, and memory) and may improve quality of life in&#xD;
      patients who have undergone radiation therapy to the brain.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well donepezil or EGb761 works in improving&#xD;
      neurocognitive function in patients who have undergone radiation therapy for primary brain&#xD;
      tumor or brain metastases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the effect of donepezil or EGb761 on neurocognitive function in patients who&#xD;
           underwent radiotherapy for a primary brain tumor or brain metastases at least 6 months&#xD;
           before study registration.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the toxicity of these drugs in these patients.&#xD;
&#xD;
        -  Determine the quality of life of patients treated with these drugs.&#xD;
&#xD;
        -  Quantify the extent of radiation-induced white matter disease and temporal lobe atrophy&#xD;
           in patients treated with these drugs.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter study.&#xD;
&#xD;
        -  Group 1 (closed to accrual 10/09/03): Patients receive oral donepezil once daily for 24&#xD;
           weeks.&#xD;
&#xD;
        -  Group 2: Patients receive oral EGb761 three times daily for 24 weeks. In both groups&#xD;
           (group 1 closed to accrual 10/09/03), treatment continues in the absence of unacceptable&#xD;
           toxicity.&#xD;
&#xD;
      In both groups (group 1 closed to accrual 10/09/03), quality of life and neurocognitive&#xD;
      assessment is performed at baseline and at weeks 6 (group 1 only), 12, 24, and 30.&#xD;
&#xD;
      Patients are followed at 6 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 70 patients (35 per treatment group) will be accrued for this&#xD;
      study within 9.5 months. (Group 1 closed to accrual 10/09/03)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2001</start_date>
  <completion_date type="Actual">August 1, 2012</completion_date>
  <primary_completion_date type="Actual">May 1, 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment type="Actual">68</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Radiation Toxicity</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>EGb761</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>donepezil hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cognitive assessment</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of primary brain tumor or brain metastases, meeting 1 of the following&#xD;
             criteria:&#xD;
&#xD;
               -  No radiographic evidence of disease&#xD;
&#xD;
               -  Stable disease, defined as no tumor progression within the past 3 months&#xD;
&#xD;
          -  Previously treated with 1 course of localized or whole brain radiotherapy of at least&#xD;
             3,000 cGy at least 6 months before study registration&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 30 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Concurrent steroid therapy allowed if on stable or decreasing dose&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent cranial radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  No concurrent surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 3 months since prior donepezil or EGb761&#xD;
&#xD;
          -  No concurrent donepezil (group 2 only)&#xD;
&#xD;
          -  No concurrent EGb761 (group 1 only) (closed to accrual 10/09/03)&#xD;
&#xD;
          -  No concurrent anticoagulants (e.g., aspirin, dipyridamole, heparin, warfarin, or&#xD;
             enoxaparin) (group 2 only)&#xD;
&#xD;
          -  No concurrent monoamine oxidase inhibitors (e.g., phenelzine or tranylcypromine)&#xD;
&#xD;
          -  No other concurrent therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward G. Shaw, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CCOP - Western Regional, Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006-2726</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Radiation Oncology Center at Rome</name>
      <address>
        <city>Rome</city>
        <state>Georgia</state>
        <zip>30165</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center at Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Upstate Carolina</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Shaw EG, Rosdhal R, D'Agostino RB Jr, Lovato J, Naughton MJ, Robbins ME, Rapp SR. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J Clin Oncol. 2006 Mar 20;24(9):1415-20.</citation>
    <PMID>16549835</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 3, 2003</study_first_submitted>
  <study_first_submitted_qc>October 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2003</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>radiation toxicity</keyword>
  <keyword>adult mixed glioma</keyword>
  <keyword>adult central nervous system germ cell tumor</keyword>
  <keyword>adult brain stem glioma</keyword>
  <keyword>adult craniopharyngioma</keyword>
  <keyword>adult medulloblastoma</keyword>
  <keyword>adult meningioma</keyword>
  <keyword>adult choroid plexus tumor</keyword>
  <keyword>adult tumors metastatic to brain</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult pilocytic astrocytoma</keyword>
  <keyword>adult subependymoma</keyword>
  <keyword>adult meningeal hemangiopericytoma</keyword>
  <keyword>adult ependymoblastoma</keyword>
  <keyword>adult anaplastic ependymoma</keyword>
  <keyword>adult pineoblastoma</keyword>
  <keyword>adult pineocytoma</keyword>
  <keyword>adult myxopapillary ependymoma</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult grade III meningioma</keyword>
  <keyword>adult oligodendroglioma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <keyword>adult ependymoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

